Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Sign up for alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

User menu

  • Log in

Search

  • Advanced search
Disease Models & Mechanisms
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

supporting biologistsinspiring biology

Disease Models & Mechanisms

Advanced search

RSS   Twitter   Facebook   YouTube

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Sign up for alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Journal Meetings
    • Workshops
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Sign up for alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
Journal Club
Modelling how initiating and transforming oncogenes cooperate to produce a leukaemic cell state
Simon E. Richardson
Disease Models & Mechanisms 2013 6: 3-5; doi: 10.1242/dmm.011288
Simon E. Richardson
1University College London Cancer Institute, Paul O’Gorman Building, 72 Huntley Street, London, WC1E 6DD, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: simon.richardson@ucl.ac.uk
  • Article
  • Info & metrics
  • PDF
Loading

Summary of and comment on a recent Cell Stem Cell paper entitled ‘Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells’ (Ashton et al., 2012).

Progress in cancer research in the decade since the human genome was published has provided more questions than answers. A theme that has emerged from this enormous body of work is that the molecular and functional heterogeneity of cancer makes the study of established cancers complex (Stratton et al., 2009). Although the degree and nature of variegation differs between cancer types, heterogeneity seems to be a fundamental characteristic of neoplasia that is acquired from the earliest stages of tumour development. At the molecular level, first-hit genetic (or epigenetic) alterations are thought to initiate a pre-malignant process by interacting with the existing machinery of the physiological cell state (Speck and Gilliland, 2002). Additional second-hit mutations are necessary to drive transformation (Knudson, 1971) and, as the malignancy progresses, further mutations lead to the development of sub-clonal variegation. The functional consequences of this molecular heterogeneity are modulated by factors that are both intrinsic and extrinsic to the cell of origin. The cell state into which mutations are introduced is of crucial importance; for example, the tissue and developmental origins of the cell (Li et al., 2005) and its position in the cellular hierarchy (e.g. somatic stem cell, committed progenitor, mature cell) (Bonnet and Dick, 1997) are among the many factors that affect the outcome of mutations. Thus, molecular and functional heterogeneity forms substrates for Darwinian natural selection at the cellular level (Anderson et al., 2011). Sub-clones ‘compete’ in a complex multicellular organism that provides many microenvironmental niches, an immune system that is hard-wired to prevent malignancy and the selective pressure of cancer therapies.

Against this background of heterogeneity, it is perhaps remarkable that drugs targeting a single part of this complex mechanism exert any clinically relevant effect, let alone afford a cure. This has been the experience clinically: drugs have been developed that can induce responses and even complete remissions, but rarely cure.

Thus, more accurate models of the cancer cell state are needed to elaborate on how early initiating and transforming oncogenes cooperate to affect a functional cellular hierarchy. A recent publication by Ashton et al. (Ashton et al., 2012) capitalised on an established mouse model of chronic myeloid leukaemia blast crisis (CML-BC) that arises from the interaction between two different fusion genes (BCR-ABL and NUP98-HOXA9) and results in a functional hierarchy that has been previously characterised (Neering et al., 2007). Ashton et al. combine this defined model of disease progression with bioinformatic microarray analysis and in silico connectivity mapping to identify candidate drugs. Could this study inform a new approach to modelling the cancer cell state?

Summary of paper

The study by Ashton et al. used a previously published model of CML-BC involving retroviral overexpression of the BCR-ABL and NUP98-HOXA9 oncogenes in mouse haematopoietic stem cell (HSC)-enriched bone marrow. Using a combination of HSC markers, these authors had previously characterised a functional hierarchy, which includes ‘leukaemia stem cells’ (LSCs; Lin– Sca+), progenitors (Lin– Sca–) and bulk populations (Lin+). A controversial interpretation of functional hierarchies in cancer is that ‘cancer stem cells’ have the greatest potential for self-renewal and are more resistant to therapy, making them the likely source of relapse. According to this theory, these cells are the key therapeutic target.

It is known that driver oncogenes can cooperate synergistically to change gene expression (McMurray et al., 2008), so the team used microarrays to identify essential cooperation response genes (CRGs) in primitive (Lin–) leukaemia cells. CRGs were defined as those genes that are activated more than additively by BCR-ABL and NUP98-HOXA9, compared with the effects of each translocation product alone. A total of 72 CRGs were identified and were validated by quantitative RT-PCR in more than 95% of cases. Of validated targets, 50 genes were upregulated. Interestingly, most CRGs that were identified had not previously been associated with leukaemia, and ranged from genes involved in signal transduction to metabolism and cell adhesion, potentially providing a broad range of previously unknown therapeutic targets for CML-BC.

The team also investigated whether the CRG expression pattern was maintained throughout the functional hierarchy of primitive LSCs, early progenitors and mature bulk cells. In total, 85% of the CRGs were common to all three fractions, suggesting that many of the core properties of oncogene cooperativity are conserved throughout the leukaemic hierarchy.

Subsequent experiments investigated whether knocking down the expression of upregulated CRGs affected leukaemia growth in vivo. The team used an in vivo short hairpin RNA (shRNA) screen to simultaneously knock down the 50 upregulated CRGs in isolated leukaemia cells in vitro, then transplanted the cells into mice. After 8 days, shRNAs against 35 of the 50 targeted CRGs were depleted in bone marrow and spleen, indicating a functional role for the corresponding CRGs in maintaining the leukaemic population. Six CRGs with varying degrees of depletion were then investigated further. Individually knocking down each of the six candidates led to reduced leukaemia engraftment, but had little effect on long-term engraftment of normal HSCs, validating the roles of these CRGs in maintaining the abnormal self-renewal characteristics of CML-BC.

The greatest degree of depletion post-transplant was induced by shRNAs against SerpinB2. To further examine the role of the encoded protein in CML-BC, SerpinB2−/− LSCs expressing BCR-ABL and NUP98-HOXA9 fusions were generated. Compared with SerpinB2-sufficient LSCs, SerpinB2−/− LSCs showed impaired engraftment. Interestingly, SerpinB2−/− LSCs expressing BCR-ABL alone had similar engraftment to SerpinB2-sufficient LSCs, supporting the idea that SerpinB2 can contribute specifically to blastic transformation of CML. Ex vivo, SerpinB2−/− LSCs showed defects in colony formation in methylcellulose, and increased apoptosis, but no change in cell cycle parameters, suggesting that SerpinB2 is necessary for the survival of LSCs prior to or during engraftment.

Previous work by Lamb et al. measured the effects of a large number of well-characterised drugs on the gene expression signatures of a range of commonly used cell lines to create a ‘connectivity map’ (Lamb et al., 2006). This group developed an Open Access online database to help researchers match disease-related gene expression profiles to candidate drugs. Using this database, Ashton et al. identified compounds that were predicted to reverse the CRG changes associated with the expression of BCR-ABL and NUP98-HOXA9. Two compounds exerted dose-dependent toxicity against leukaemia cells, particularly LSCs, with minimal toxicity to wild-type HSCs.

Finally, the team validated their findings using primary samples from patients with CML-BC (all of which carried BCR-ABL translocations, but a variety of other cooperating mutations). The authors carried out gene expression profiling for a subset of the CRGs identified in their mouse experiments, and showed that 13 of 33 evaluable genes were also dysregulated in the patient samples. Notably, in contrast to what was found in mice, SerpinB2 was not identified as a CRG in the patient samples. When the human CML-BC CRG profile was analysed on the online connectivity map, small-molecule inhibitors were suggested that were similar to those identified based on the analysis of mouse CRGs; again, these compounds showed preferential toxicity to human leukaemia cells (particularly progenitors) compared with control cells.

In summary, the study by Ashton et al. combines previously published techniques to address three of the most vexing problems in modelling cancer: the unpredictable cooperativity of early driver mutations on cell state, functional heterogeneity and the identification of candidate drugs that can reverse this state.

Unresolved issues and future directions

Suitability of mouse models of malignancy

An obvious concern with this study is how closely the transcriptional profile identified in the mouse model mirrors that of human CML-BC. Retroviral overexpression of just two oncogenes in HSCs from inbred laboratory mice cannot model the physiological cell state of transformed human HSCs, nor the molecular and functional heterogeneity established during the human disease. Untreated CML in humans runs a chronic course, longer than the entire life expectancy of a mouse. This time course provides the opportunity to build up a range of different mutations and sub-clones, with blast crisis usually preceded by an accelerated phase of variable duration, suggesting a multi-step pathogenesis. Nevertheless, Ashton et al. used a well-characterised mouse model, and it should be pointed out that it is surprisingly difficult to make accurate mouse models of the various morphological (let alone myriad molecular) leukaemic subtypes (Tsuzuki et al., 2004). Despite the caveats of using mouse models, the authors identified significant overlap in both the gene expression profile and drug sensitivity between their mouse model and the molecularly heterogeneous human disease samples.

CRGs in molecular and functional heterogeneity

The identification of CRGs could be a strategy to sort through heterogeneity. Excitingly, this study seems to show that a small number of CRGs are preserved throughout the functional leukaemic hierarchy. This suggests that, at least in CML-BC, the CRGs drive a cancer cell state through which a physiological cellular hierarchy can be expressed. However, this study does not seek to validate a CRG approach to identifying drugs that circumvent molecular heterogeneity. First, it is believed that many leukaemias are preceded by the presence of an ancestrally initiated, but non-transformed, ‘pre-leukaemic clone’ harbouring the first-hit mutation (Wiemels et al., 1999; Hong et al., 2008). Work in the paradigmatic TEL-AML1 childhood acute lymphoblastic leukaemia (ALL) has clearly shown that such ‘pre-leukaemic’ clones commonly initiate relapse after chemotherapy (Mullighan et al., 2008). Because drugs targeting CRG profiles can only reverse the transformed state, they would not be expected to eradicate the pre-leukaemic compartment from which relapse can be initiated. Second, even in relatively tractable childhood leukaemias, such as TEL-AML1 ALL, there are several possible transforming second hits (Bateman et al., 2010). It is not known whether these second hits cooperate with the first hit in a convergent manner, to produce a common gene-expression profile, or whether they provide a diversity of potentially overlapping cell states. It is clear that transformation is more than a two-hit process in most cancers, and certainly several mutations are present in most clones in most patients at diagnosis.

So, does a core CRG profile persist through this molecular heterogeneity? The hope is that, despite the molecular complexity, oncogenes and transcription factors interact in a predictable way, permitting only a limited number of cell state ‘solutions’ (Enver et al., 2009). This moves us away from targeting individual molecular lesions to an approach in which drugs are used to make the cancer cell state solution thermodynamically ‘unfavourable’.

Targeting CRGs for drug development

Using model systems with defined genetic events to identify synergistic changes to gene expression that occur during disease progression provides a manageable list of candidate genes to examine. The proportion of CRGs validated as having functional relevance during the shRNA screen is impressive, and provides an array of unexpected novel drug targets. However, beyond the identification of individual drug targets, connectivity mapping can identify drugs that broadly antagonise the CRG profile. This not only provides a short-cut in drug screening, but can also identify compounds with efficacy in both a mouse model of CML-BC and on a heterogeneous selection of human CML-BC samples.

As Lamb et al. noted in their earlier paper (Lamb et al., 2006), the design of the reference connectivity map also used by Ashton et al. seeks to simplify biological complexity. Variables that are standardised in these maps include: cell types used; the dose, timing and combination of drugs assayed; and the measured output (mRNA, protein, epigenetic or functional changes). It remains difficult to predict whether a drug-induced change in the gene expression profile of a specific cell line will translate into functional changes to cancer cells in vivo, but this work shows that in silico connectivity mapping is a promising approach.

Conclusion

The past decade of cancer research has witnessed a revolution in our capacity to measure and analyse biological data, but, when deployed on human cancer samples, such analyses have revealed unexpected complexity. This study suggests that the earliest lesions cooperate synergistically to define the cancer cell state and that we can use these data to screen candidate drugs in silico. Perhaps the biggest challenge to overcome before this approach can be fully exploited is the lack of a cellular ‘toolbox’ that can accurately model the earliest cell states of multiple different cancers. An ideal system would compare wild-type human cells in their physiological cell state to those harbouring authentic initiating first-hit and transforming second-hit mutations. Directed differentiation of human pluripotent stem cells might provide the ability to model physiological cell states in vitro, whereas the ability to precisely genome engineer these cells with targeted nucleases could be used to model the earliest stages of cancer. An exciting possibility is that disease-specific model systems will identify disease-defining CRG profiles that persist through clonal diversification, allowing the identification of drugs that can more broadly antagonise the cancer cell state (Stratton, 2009).

  • © 2012. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms.

REFERENCES

  1. ↵
    1. Anderson, K.,
    2. Lutz, C.,
    3. van Delft, F. W.,
    4. Bateman, C. M.,
    5. Guo, Y.,
    6. Colman, S. M.,
    7. Kempski, H.,
    8. Moorman, A. V.,
    9. Titley, I.,
    10. Swansbury, J.,
    11. et al.
    (2011). Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356–361.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Ashton, J. M.,
    2. Balys, M.,
    3. Neering, S. J.,
    4. Hassane, D. C.,
    5. Cowley, G.,
    6. Root, D. E.,
    7. Miller, P. G.,
    8. Ebert, B. L.,
    9. McMurray, H. R.,
    10. Land, H.,
    11. et al.
    (2012). Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell 11, 359–372.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Bateman, C. M.,
    2. Colman, S. M.,
    3. Chaplin, T.,
    4. Young, B. D.,
    5. Eden, T. O.,
    6. Bhakta, M.,
    7. Gratias, E. J.,
    8. van Wering, E. R.,
    9. Cazzaniga, G.,
    10. Harrison, C. J.,
    11. et al.
    (2010). Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. Blood 115, 3553–3558.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Bonnet, D. and
    2. Dick, J. E.
    (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Enver, T.,
    2. Pera, M.,
    3. Peterson, C. and
    4. Andrews, P. W.
    (2009). Stem cell states, fates, and the rules of attraction. Cell Stem Cell 4, 387–397.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Hong, D.,
    2. Gupta, R.,
    3. Ancliff, P.,
    4. Atzberger, A.,
    5. Brown, J.,
    6. Soneji, S.,
    7. Green, J.,
    8. Colman, S.,
    9. Piacibello, W.,
    10. Buckle, V.,
    11. et al.
    (2008). Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319, 336–339.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Knudson, A. G. Jr.
    (1971). Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68, 820–823.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Lamb, J.,
    2. Crawford, E. D.,
    3. Peck, D.,
    4. Modell, J. W.,
    5. Blat, I. C.,
    6. Wrobel, M. J.,
    7. Lerner, J.,
    8. Brunet, J. P.,
    9. Subramanian, A.,
    10. Ross, K. N.,
    11. et al.
    (2006). The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Li, Z.,
    2. Godinho, F. J.,
    3. Klusmann, J. H.,
    4. Garriga-Canut, M.,
    5. Yu, C. and
    6. Orkin, S. H.
    (2005). Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat. Genet. 37, 613–619.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. McMurray, H. R.,
    2. Sampson, E. R.,
    3. Compitello, G.,
    4. Kinsey, C.,
    5. Newman, L.,
    6. Smith, B.,
    7. Chen, S. R.,
    8. Klebanov, L.,
    9. Salzman, P.,
    10. Yakovlev, A.,
    11. et al.
    (2008). Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature 453, 1112–1116.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Mullighan, C. G.,
    2. Phillips, L. A.,
    3. Su, X.,
    4. Ma, J.,
    5. Miller, C. B.,
    6. Shurtleff, S. A. and
    7. Downing, J. R.
    (2008). Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322, 1377–1380.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Neering, S. J.,
    2. Bushnell, T.,
    3. Sozer, S.,
    4. Ashton, J.,
    5. Rossi, R. M.,
    6. Wang, P. Y.,
    7. Bell, D. R.,
    8. Heinrich, D.,
    9. Bottaro, A. and
    10. Jordan, C.T.
    (2007). Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 110, 2578–2585.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Speck, N. A. and
    2. Gilliland, D. G.
    (2002). Core-binding factors in haematopoiesis and leukaemia. Nat. Rev. Cancer 2, 502–513.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Stratton, M. R.,
    2. Campbell, P. J. and
    3. Futreal, P. A.
    (2009). The cancer genome. Nature 458, 719–724.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Tsuzuki, S.,
    2. Seto, M.,
    3. Greaves, M. and
    4. Enver, T.
    (2004). Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc. Natl. Acad. Sci. USA 101, 8443–8448.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Wiemels, J. L.,
    2. Cazzaniga, G.,
    3. Daniotti, M.,
    4. Eden, O. B.,
    5. Addison, G. M.,
    6. Masera, G.,
    7. Saha, V.,
    8. Biondi, A. and
    9. Greaves, M. F.
    (1999). Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354, 1499–1503.
    OpenUrlCrossRefPubMedWeb of Science
Previous ArticleNext Article
Back to top
Previous ArticleNext Article

This Issue

RSSRSS

 Download PDF

Email

Thank you for your interest in spreading the word on Disease Models & Mechanisms.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Modelling how initiating and transforming oncogenes cooperate to produce a leukaemic cell state
(Your Name) has sent you a message from Disease Models & Mechanisms
(Your Name) thought you would like to see the Disease Models & Mechanisms web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Journal Club
Modelling how initiating and transforming oncogenes cooperate to produce a leukaemic cell state
Simon E. Richardson
Disease Models & Mechanisms 2013 6: 3-5; doi: 10.1242/dmm.011288
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Journal Club
Modelling how initiating and transforming oncogenes cooperate to produce a leukaemic cell state
Simon E. Richardson
Disease Models & Mechanisms 2013 6: 3-5; doi: 10.1242/dmm.011288

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts

Please log in to add an alert for this article.

Sign in to email alerts with your email address

Article navigation

  • Top
  • Article
    • Summary of paper
    • Unresolved issues and future directions
    • Conclusion
    • REFERENCES
  • Info & metrics
  • PDF

Related articles

Cited by...

More in this TOC section

  • Finding NECA: zebrafish screen identifies key signalling pathway in β-cell regeneration
  • Lactate-starved neurons in ALS
Show more Journal Club

Similar articles

Other journals from The Company of Biologists

Development

Journal of Cell Science

Journal of Experimental Biology

Biology Open

Advertisement

DMM and COVID-19

We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.

Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.


Professor Elizabeth Patton appointed as DMM’s next Editor-in-Chief

We are pleased to announce that The Company of Biologists directors have appointed Professor Elizabeth Patton as DMM's new Editor-in-Chief. As Paresh Vyas writes in his Editorial, Liz ‘brings vitality and a passion for the remit of DMM, and is deeply embedded in the community.’


Did you know DMM Conference Travel Grants can be used for online meetings?

With travel restrictions still in place, we want to continue supporting early-career researchers in their careers. DMM’s Conference Travel Grants can now be used to attend virtual and online scientific meetings, workshops, conferences and training courses.

The current application round closes on 8 February 2021 – find out more.


Identification of MYOM2 as a candidate gene in hypertrophic cardiomyopathy and Tetralogy of Fallot, and its functional evaluation in the Drosophila heart

Research from Silke Sperling and colleagues uses Drosophila to identify MYOM2 as a candidate gene in congenital heart malformations in this issue’s Editor’s choice.


C. elegans as a disease model

A new Research article from Doyle et al., models spinal muscular atrophy in C. elegans to show that that targeting therapies to muscle cells is more effective than neuronal delivery. Find more research using C. elegans as a disease model in our latest subject collection.


Call for papers – The RAS Pathway: Diseases, Therapeutics and Beyond

Our upcoming special issue is now welcoming submissions until 1 April 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway. Find out more about the issue and how to submit your manuscript.


Interview – Kim Landry-Truchon and Nicolas Houde

In an interview, first authors Kim Landry-Truchon and Nicolas Houde discuss their mouse model of the early stages of pleuropulmonary blastoma, reflecting on the implications of their work and the future of their field.

Articles

  • Accepted manuscripts
  • Issue in progress
  • Latest complete issue
  • Issue archive
  • Archive by article type
  • Subject collections
  • Interviews
  • Sign up for alerts

About us

  • About DMM
  • Editors and Board
  • Editor biographies
  • Travelling Fellowships
  • Grants and funding
  • Journal Meetings
  • Workshops
  • The Company of Biologists

For Authors

  • Submit a manuscript
  • Aims and scope
  • Presubmission enquiries
  • Article types
  • Manuscript preparation
  • Cover suggestions
  • Editorial process
  • Promoting your paper
  • Open Access
  • Biology Open transfer

Journal Info

  • Journal policies
  • Rights and permissions
  • Media policies
  • Reviewer guide
  • Sign up for alerts

Contact

  • Contact DMM
  • Advertising
  • Feedback

Twitter   YouTube   LinkedIn

© 2021   The Company of Biologists Ltd   Registered Charity 277992